Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NEERA GROVER

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1023169489
CMS profile
136769
Location
APPLE VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$167.33

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $167.33 8

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $44.14 2
ABBVIE INC. $39.07 2
Gilead Sciences, Inc. $27.15 1
GENZYME CORPORATION $25.60 1
Braintree Laboratories, Inc. $15.85 1
Janssen Biotech, Inc. $15.52 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NEERA GROVER

NPI 1023169489 · CMS profile ID 136769

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

APPLE VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023169489?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NEERA GROVER, NPI 1023169489, CMS profile ID 136769. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023169489?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NEERA GROVER, NPI 1023169489, CMS profile ID 136769. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023169489?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NEERA GROVER, NPI 1023169489, CMS profile ID 136769, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1023169489?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $167.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $20.9512/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048291205 CMS
GENZYME CORPORATION $25.6010/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049720485 CMS
ABBVIE INC. $15.7310/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997396233 CMS
ABBVIE INC. $23.3408/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997396231 CMS
Braintree Laboratories, Inc. $15.8506/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006448029 CMS
Janssen Biotech, Inc. $15.5205/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988018243 CMS
Gilead Sciences, Inc. $27.1503/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025590427 CMS
Merck Sharp & Dohme LLC $23.1901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048730185 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $269.22 8
PY2020 $67.05 2
PY2021 $340.98 21
PY2022 $269.57 17
PY2023 $167.33 8
PY2024 $625.50 24
PY2025 $657.26 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $200,027.03 74
PY2024 Principal investigator $100,849.46 51
PY2023 Principal investigator $219,334.14 67
PY2022 Principal investigator $30,141.50 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,729.00 12/14/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100937
Principal investigator 1 Janssen Research & Development, LLC $4,729.00 12/14/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100941
Principal investigator 1 Janssen Research & Development, LLC $1,303.42 12/11/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157461
Principal investigator 1 Janssen Research & Development, LLC $3,100.00 12/08/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157463
Principal investigator 1 Janssen Research & Development, LLC $1,253.09 11/24/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157455
Principal investigator 1 Janssen Research & Development, LLC $1,596.40 11/24/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157457
Principal investigator 1 Janssen Research & Development, LLC $359.00 11/20/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100933
Principal investigator 1 SANOFI US SERVICES INC. $1,725.00 11/14/2023 Non-covered Recipient Entity
Om Research Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1035960825
Principal investigator 1 Janssen Research & Development, LLC $1,675.21 11/13/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157459
Principal investigator 1 Janssen Research & Development, LLC $5,524.00 10/26/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100925
Principal investigator 1 Janssen Research & Development, LLC $3,977.00 10/26/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804UCO2001 No dispute reported 06/30/2026 986100945
Principal investigator 1 Janssen Research & Development, LLC $363.00 10/19/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100929
Principal investigator 1 SANOFI US SERVICES INC. $1,725.00 10/10/2023 Non-covered Recipient Entity
Om Research Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1035960787
Principal investigator 1 Janssen Research & Development, LLC $1,215.18 10/05/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157453
Principal investigator 1 Janssen Research & Development, LLC $299.00 10/02/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100915
Principal investigator 1 Janssen Research & Development, LLC $5,205.00 10/02/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100919
Principal investigator 1 Janssen Research & Development, LLC $5,533.00 10/02/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100923
Principal investigator 1 Janssen Research & Development, LLC $724.47 09/21/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157449
Principal investigator 1 Janssen Research & Development, LLC $4,200.00 09/21/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157451
Principal investigator 1 Janssen Research & Development, LLC $777.73 08/28/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10.00 08/28/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039760997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10.00 08/28/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039804325
Principal investigator 1 Janssen Research & Development, LLC $13,200.00 08/10/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157445
Principal investigator 1 Janssen Research & Development, LLC $6,900.00 07/31/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157441
Principal investigator 1 Janssen Research & Development, LLC $2,700.00 07/31/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157443
Principal investigator 1 Janssen Research & Development, LLC $299.00 07/20/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100899
Principal investigator 1 Janssen Research & Development, LLC $4,978.00 07/20/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100903
Principal investigator 1 Janssen Research & Development, LLC $5,940.00 07/20/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100907
Principal investigator 1 Janssen Research & Development, LLC $363.00 07/14/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100881
Principal investigator 1 Janssen Research & Development, LLC $363.00 07/14/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100883
Principal investigator 1 Janssen Research & Development, LLC $363.00 07/14/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100887
Principal investigator 1 Janssen Research & Development, LLC $124.00 07/14/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100891
Principal investigator 1 Janssen Research & Development, LLC $649.00 07/14/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.00 07/13/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 977165295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,150.00 07/13/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 977165315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,100.00 07/13/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 977165325
Principal investigator 1 Janssen Research & Development, LLC $3,010.00 07/03/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804UCO2001 No dispute reported 06/30/2026 986100911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $191.90 06/23/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039727343
Principal investigator 1 PFIZER INC. $606.90 06/02/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046499581
Principal investigator 1 Janssen Research & Development, LLC $1,150.00 05/22/2023 Non-covered Recipient Entity
Om Rsrch Llc
CNTO1959CRD3004 No dispute reported 06/30/2026 986100977
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 05/22/2023 Non-covered Recipient Entity
Om Rsrch Llc
CNTO1959CRD3004 No dispute reported 06/30/2026 986100981
Principal investigator 1 PFIZER INC. $429.00 05/03/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046500061
Principal investigator 1 PFIZER INC. $277.00 05/03/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046504439
Principal investigator 1 PFIZER INC. $1,243.20 05/03/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046513323
Principal investigator 1 PFIZER INC. $5,780.00 05/03/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046514252
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,400.00 05/01/2023 Non-covered Recipient Entity
Om Research Llc
A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1027493395
Principal investigator 1 PFIZER INC. $792.00 04/24/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046501551
Principal investigator 1 Janssen Research & Development, LLC $820.00 04/19/2023 Non-covered Recipient Entity
Om Rsrch Llc
CNTO1959CRD3004 No dispute reported 06/30/2026 986100985
Principal investigator 1 Janssen Research & Development, LLC $3,870.00 04/10/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157439
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,154.89 03/28/2023 Non-covered Recipient Entity
Om Research Llc - Apple Valley - Clinedge - Ppds
UC Community Study No dispute reported 06/30/2026 1027493433
Principal investigator 1 SANOFI US SERVICES INC. $17,850.00 03/27/2023 Non-covered Recipient Entity
Om Research Llc
ACT - POC clinical study No dispute reported 06/30/2026 1035960775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $88.00 03/08/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039849517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,348.75 03/01/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039848335
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/02/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100865
Principal investigator 1 Janssen Research & Development, LLC $1,600.00 02/02/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100869
Principal investigator 1 Janssen Research & Development, LLC $5,500.00 02/02/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100873
Principal investigator 1 Janssen Research & Development, LLC $7,740.00 02/02/2023 Non-covered Recipient Entity
Om Rsrch Llc
78934804CRD2001 No dispute reported 06/30/2026 986100877
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 01/30/2023 Non-covered Recipient Entity
Om Rsrch Llc
CNTO1959CRD3004 No dispute reported 06/30/2026 986100857
Principal investigator 1 Janssen Research & Development, LLC $1,600.00 01/30/2023 Non-covered Recipient Entity
Om Rsrch Llc
CNTO1959CRD3004 No dispute reported 06/30/2026 986100859
Principal investigator 1 Janssen Research & Development, LLC $5,500.00 01/30/2023 Non-covered Recipient Entity
Om Rsrch Llc
CNTO1959CRD3004 No dispute reported 06/30/2026 986100861
Principal investigator 1 Janssen Research & Development, LLC $7,440.00 01/30/2023 Non-covered Recipient Entity
Om Rsrch Llc
CNTO1959CRD3004 No dispute reported 06/30/2026 986100863
Principal investigator 1 Janssen Research & Development, LLC $11,600.00 01/23/2023 Non-covered Recipient Entity
OM RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986157437
Principal investigator 1 PFIZER INC. $7,000.00 01/04/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046348123
Principal investigator 1 PFIZER INC. $2,188.00 01/04/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046497825
Principal investigator 1 PFIZER INC. $750.00 01/04/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046514105
Principal investigator 1 PFIZER INC. $750.00 01/04/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046514271
Principal investigator 1 PFIZER INC. $792.00 01/04/2023 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1046514291